SPRY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ARS Pharmaceuticals Inc (SPRY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's innovative product pipeline, strong hedge fund interest, and positive analyst ratings with significant upside potential make it a solid choice for long-term growth.
The MACD is positive and contracting, RSI is neutral at 57.485, and moving averages are converging, indicating no strong trend. Key support is at 8.664, and resistance is at 10.078. The stock is trading near its pivot level of 9.371.
Analyst ratings are highly favorable, with price targets raised to $25 and $30, citing the disruptive potential of the company's needle-free epinephrine product, neffy. Hedge funds are significantly increasing their positions, with a 326% rise in buying activity last quarter.
No recent news or congress trading data available. The stock has shown a slight regular market decline of -2.53%, and technical indicators do not show a strong bullish trend.
Financial data is unavailable for analysis, but the company is expected to see significant growth driven by its product pipeline, including neffy and ARS-2.
Analysts have given an Overweight and Outperform rating, with price targets of $25 and $30. They highlight the potential for long-term upside from product adoption and future launches.
